Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.46 |
| ▸ | FLT1 | P17948 | 3/20 | 0.43 |
| ▸ | VEGFA | P15692 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775689 | 0.90 | EGLN1 (0.51) | EGLN3EGLN1FLT1VEGFA | |
| SCHEMBL2775539 | 0.87 | EGLN1 (0.54) | EGLN3EGLN1FLT1VEGFA | |
| SCHEMBL2775364 | 0.87 | EGLN1 (0.53) | EGLN3EGLN1FLT1VEGFA | |
| SCHEMBL2777174 | 0.86 | EGLN1 (0.56) | EGLN3EGLN1FLT1VEGFA | |
| SCHEMBL2775886 | 0.86 | EGLN1 (0.56) | EGLN3EGLN1FLT1VEGFA | |
| SCHEMBL2774355 | 0.86 | EGLN1 (0.48) | EGLN3EGLN1FLT1VEGFA | |
| SCHEMBL2775639 | 0.85 | EGLN1 (0.42) | EGLN3EGLN1FLT1VEGFA | |
| SCHEMBL2775029 | 0.84 | EGLN1 (0.59) | EGLN3EGLN1FLT1VEGFA | |
| SCHEMBL2776124 | 0.83 | EGLN1 (0.45) | EGLN3EGLN1 | |
| SCHEMBL2777651 | 0.83 | EGLN1 (0.57) | EGLN3EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227475-B1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN INC (US) | 2014-02-19 | — | — | EP | claimed |
| US-8269008-B2 | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions | FIBROGEN, INC. (US) | 2012-09-18 | — | — | US | claimed |
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2010-12-02 | — | — | US | claimed |
| EP-2227475-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073669-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2009-06-11 | — | — | WO | claimed |
| EP-2227475-B1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN INC (US) | 2014-02-19 | — | — | EP | disclosed |
| US-8269008-B2 | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions | FIBROGEN, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2227475-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073669-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | HIF1AN, HIF1A, EGLN2 | EGLN3 4/4885EGLN1 5/4885FLT1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.